Oncology Corporate Profile
EMD Serono, Inc. is a leader in the U.S. biopharmaceutical industry. The Company has more than 1,100 employees throughout the United States with fully integrated commercial, clinical, and research operations near Boston and headquarters in Rockland, Massachusetts. EMD Serono has more than 30 trials in our global clinical pipeline, focused on developing innovative therapies for cancer and neurodegenerative diseases such as multiple sclerosis and Parkinson's disease.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|avelumab||anti-PD-L1 mAb||Non Small Cell Lung Cancer (NSCLC)||III||Pfizer|
|Erbitux_ / cetuximab||anti-EGFR monoclonal antibody||1st line metastatic Gastric cancer||III|
|Erbitux_ / cetuximab||anti-EGFR monoclonal antibody||Adjuvant Colorectal cancer||III|
|Stimuvax_ / BLP25 liposome vaccine||immunotherapy||2nd line metastatic Breast cancer||III||Oncothyreon|
|Stimuvax_ / BLP25 liposome vaccine||immunotherapy||Non Small Cell Lung Cancer (NSCLC)||III||Oncothyreon|
|EMD 525797 (DI17E6)||IgG2 monoclonal antibody||1st line metastatic Colorectal cancer||II|
|cilengitide||integrin inhibitor||2nd line metastatic Glioblastoma Multiforme (GBM)||II|
|IMO-2055 (EMD 1201081) (+ cetuximab)||toll-like receptor 9 (TLR9)||2nd line metastatic squamous cell carcinoma of the head and neck||II|
|abituzumab||anti-integrin mAb||Colorectal cancer||II|
|sym004||anti-EGFR mAb||Colorectal cancer||II|
|adecatumumab / MT201||anti-EpCAM monoclonal antibody||Colorectal cancer||II||Micromet|
|DI17E6||anti-EpCAM monoclonal antibody||Colorectal cancer||II|
|tepotinib||c-Met kinase inhibitor||Hepatocellular carcinoma (HCC)||II|
|cilengitide||integrin inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|TH-302||hypoxia-activated prodrug||Non Small Cell Lung Cancer (NSCLC)||II|
|cilengitide||integrin inhibitor||Squamous cell cancer of the head and neck (SCCHN)||II|
|Erbitux_ / cetuximab (+ FOLFOX)||anti-EGFR monoclonal antibody||1st line metastatic Colorectal cancer||II|
|Erbitux_ / cetuximab||anti-EGFR monoclonal antibody||Breast cancer||II|
|Stimuvax_ / BLP25 liposome vaccine||immunotherapy||Prostate cancer||II||Oncothyreon|
|IMO-2055 (EMD 1201081) (+ cisplatin, fluorouracil and cetuximab)||toll-like receptor 9 (TLR9)||1st line metastatic squamous cell carcinoma of the head and neck||I|
|IMO-2055 (EMD 1201081) (+ erlotinib and bevacizumab)||toll-like receptor 9 (TLR9)||2nd line metastatic Non Small Cell Lung Cancer (NSCLC)||I|
|tepotinib||c-Met kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|EMD 1214063||c-Met kinase inhibitor||Various cancer types||I|
|AS703026||MEK inhibitor||Various cancer types||I|
|evofosfamide / TH-302||hypoxia-activated prodrug||Various cancer types||I|
View additional information on product candidates here »
6/6/2016 02:02 pm
(Forbes) June 6, 2016 - Myriad is among several companies that are facing a headwind of resistance from, among others, the insurance industry, which has doubts about the value of testing so many genes.
2/17/2016 12:01 pm
(ACS) Feb 17, 2016 - Biannual Outstanding Achievement Award is granted to encourage accredited cancer programs to raise the bar on quality cancer care.
2/10/2016 11:04 am
(MSK) Feb 10, 2016 - Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care.
1/20/2016 12:00 pm
(AACR) Jan 20, 2016 - Vice President Biden invited leaders from the American Association for Cancer Research (AACR) to provide their thoughts and guidance at today's special session, "Cancer Moonshot: A Call to Action," at the World Economic Forum in Davos, Switzerland.
12/18/2015 11:55 am
(Boston Globe) Dec 18, 2015 - Cancer drug maker Ariad Pharmaceuticals Inc. of Cambridge, which reached a deal earlier this year to remove its founder and longtime chief executive, Friday said it had snatched a top executive from Rockland-based EMD Serono to take the helm at Ariad.
9/29/2015 12:36 pm
(StreetInsider) Sept 29, 2015 - EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt,Germany, announced today the appointment of Joseph Leveque, M.D. as U.S. Chief Medical Officer.
8/18/2015 12:00 pm
(BBC News) Aug 18, 2015 - A hospital scan normally used to detect cancer could be used to steer tumour killing treatments to hard-to-reach targets in the body, say scientists. The UK team at Sheffield University deployed the magnetic power of MRI scans to control the movement of a specially designed injectable cancer therapy.
8/17/2015 11:04 am
(U.S. News & World Report) Aug 13, 2015 - It seems like a good idea to pay physicians better when their patients do better, but that may not be the case.
5/18/2015 12:01 pm
(Washington Post) May 18, 2015 - Inova’s plan to develop a medical campus dedicated to cancer research, genomics and personalized medicine is getting a major boost from someone who knows a thing or two about building.
5/6/2015 10:22 am
(EMD Serono) May 6, 2015 - EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib) as part of its global strategic alliance with Pfizer.
3/26/2015 11:05 am
(Medscape Medical News) Mar 25, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine.
3/18/2015 12:01 pm
(MarketWatch) Mar 17, 2015 - Journey Forward, a leader in survivorship care planning, and Electronic Registry Services (ERS), a leading provider of cancer registry software, today announced a successful implementation that enhances the use of patient data in after-care plans.
3/17/2015 06:04 am
(PharmaTimes [UK]) Mar 17, 2015 - Novartis has been given the green light in Europe for Jakavi to treat a rare blood cancer.
3/12/2015 12:00 pm
(NPR/Shots blog) Mar 11, 2015 - Many scientists are failing to live up to a 2007 law that requires them to report the results of their clinical trials to a public website, according to a study in Thursday's New England Journal of Medicine.
2/23/2015 12:01 pm
(Reuters) Feb 23, 2015 - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.
2/19/2015 12:02 pm
(BBC News) Feb 18, 2015 - The price the NHS in England agrees to pay for new medicines is too high, causing more harm than good overall, an analysis suggests.
1/28/2015 12:00 pm
(Washington Post/Speaking of Science) Jan 28, 2015 - The eggs were used as a proxy for a much more serious endeavor: making cancer research more time and cost efficient.
1/27/2015 12:01 pm
(HealthLeaders Media) Jan 27, 2015 - HHS officials highlight a three-year payment reform timeline, which calls for boosting fee-for-service Medicare reimbursements and increasing reimbursements linked to quality and value.
1/27/2015 12:01 pm
(The News & Observer [Raleigh, NC]) Jan 26, 2015 - Duke University’s Robert Califf will step down as vice chancellor at Duke’s School of Medicine to head the nation’s oversight of drug safety and tobacco regulation. The U.S. Food and Drug Administration and Duke announced Califf’s appointment Monday.
1/8/2015 11:05 am
(Medscape Medical News) Jan 7, 2015 - For patients with ovarian cancer who are in remission, the probability of remaining disease-free improves considerably over time, and conditional disease-free survival might be a good estimate of prognosis for these patients, according to a new study.
12/4/2014 10:05 am
(FDA.gov) Dec 4, 2014 - The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease.
11/14/2014 05:05 am
(AACR) Nov 14, 2014 - Secondhand smoke in the confined space of a motor vehicle resulted in exposure to several tobacco smoke toxins, and may ultimately increase risk for cancer and for respiratory and cardiovascular diseases in nonsmokers, according to a new study.
11/14/2014 05:04 am
(MedPage Today) Nov 13, 2014 - Liver transplant is the best treatment option for people with HIV and hepatocellular carcinoma, a researcher said here.
11/7/2014 06:01 am
(Harvard Medical School) Nov 6, 2014 - Most cancer deaths occur because of metastasis, yet progress in preventing and treating migratory cancer cells has been slow.
9/29/2014 02:55 pm
(Boston Business Journal) Sept 27, 2014 - EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million.
9/17/2014 12:13 pm
(Boston Globe) Sept 17, 2014 - EMD Serono Inc., a Rockland-based subsidiary of Germany’s Merck KGaA, and Sutro Biopharma said Wednesday that they have agreed to collaborate on developing antibody drug conjugates that target such diseases as cancer.
7/29/2014 06:04 am
(Yahoo! Finance) July 29, 2014 - First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC); mMCC is a rare and aggressive skin cancer lacking effective treatments.
7/10/2014 07:00 am
(Ventana) July 10, 2014 - Ventana Medical Systems, Inc., a member of the Roche Group, today announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays.
6/24/2014 06:02 am
(Merck Serono) June 24, 2014 – Merck Serono, the biopharmaceutical division of Merck, and Mersana Therapeutics, Inc., Cambridge, Mass., U.S., announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).
6/12/2014 07:00 am
(MarketWatch) June 12, 2014 - MorphoSys AG and Merck today announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.